|Trade names||RabAvert, Rabipur, Rabivax, others|
|Intramuscular injection (IM)|
|(what is this?)|
The rabies vaccine is a vaccine used to prevent rabies. There are a number of rabies vaccines available that are both safe and effective. They can be used to prevent rabies before, and for a period of time after, exposure to the rabies virus, which is commonly caused by a dog bite or a bat bite.
Doses are usually given by injection into the skin or muscle. After exposure, the vaccination is typically used along with rabies immunoglobulin. It is recommended that those who are at high risk of exposure be vaccinated before potential exposure. Rabies vaccines are effective in humans and other animals, and vaccinating dogs is very effective in preventing the spread of rabies to humans. A long-lasting immunity to the virus develops after a full course of treatment.
Rabies vaccines may be used safely by all age groups. About 35 to 45 percent of people develop a brief period of redness and pain at the injection site, and 5 to 15 percent of people may experience fever, headaches, or nausea. After exposure to rabies, there is no contraindication to its use, since the untreated virus is always fatal.
The first rabies vaccine was introduced in 1885 and was followed by an improved version in 1908. Millions of people globally are vaccinated against the virus. It is on the World Health Organization's List of Essential Medicines.
The World Health Organization (WHO) recommends vaccinating those who are at high risk of the disease, such as children who live in areas where it is common. Other groups may include veterinarians, researchers, or people planning to travel to regions where rabies is common. Three doses of the vaccine are given over a one-month period on days zero, seven, and either twenty-one or twenty-eight.
For individuals who have been potentially exposed to the virus, four doses over two weeks are recommended, as well as an injection of rabies immunoglobulin with the first dose. This is known as post-exposure vaccination. For people who have previously been vaccinated, only a single dose of the rabies vaccine is required. However, vaccination after exposure is neither a treatment nor a cure for rabies; it can only prevent the development of rabies in a person if given before the virus reaches the brain. Because the rabies virus has a relatively long incubation period, post-exposure vaccinations are typically highly effective.
Immunity following a course of doses is typically long lasting, and additional doses are usually not needed unless the person has a high risk of contracting the virus. Those at risk may have tests done to measure the amount of rabies antibodies in the blood, and then get rabies boosters as needed. Following administration of a booster dose, one study found 97% of immunocompetent individuals demonstrated protective levels of neutralizing antibodies after ten years.
Rabies vaccines are safe in all age groups. About 35 to 45 percent of people develop a brief period of redness and pain at the injection site, and 5 to 15 percent of people may experience fever, headaches, or nausea. Because of the certain fatality of the virus, receiving the vaccine is always advisable.
Vaccines made from nerve tissue are used in a few countries, mainly in Asia and Latin America, but are less effective and have greater side effects. Their use is thus not recommended by the World Health Organization.
In addition to these developments, newer and less expensive purified chicken embryo cell vaccines (CCEEV) and purified Vero cell rabies vaccines are now available and are recommended for use by the WHO. The purified Vero cell rabies vaccine uses the attenuated Wistar strain of the rabies virus, and uses the Vero cell line as its host. CCEEVs can be used in both pre- and post-exposure vaccinations. CCEEVs use inactivated rabies virus grown from either embryonated eggs or in cell cultures and are safe for use in humans and animals.
Virtually all infections with rabies resulted in death until two French scientists, Louis Pasteur and Émile Roux, developed the first rabies vaccination in 1885. Nine-year-old Joseph Meister (1876–1940), who had been mauled by a rabid dog, was the first human to receive this vaccine. The treatment started with a subcutaneous injection on 6 July 1885, at 8:00 pm, which was followed with 12 additional doses administered over the following 10 days. The first injection was derived from the spinal cord of an inoculated rabbit which had died of rabies 15 days earlier. All the doses were obtained by attenuation, but later ones were progressively more virulent.
The Pasteur-Roux vaccine attenuated the harvested virus samples by allowing them to dry for five to ten days. Similar nerve tissue-derived vaccines are still used in some countries, and while they are much cheaper than modern cell culture vaccines, they are not as effective. Neural tissue vaccines also carry a certain risk of neurological complications.
When the modern cell-culture rabies vaccine was first introduced in the early 1980s, it cost $45 per dose was considered to be too expensive. The cost of the rabies vaccine continues to be a limitation to acquiring pre-exposure rabies immunization for travelers from developed countries. In 2015 in the United States, a course of three doses could cost over $1,000, while in Europe a course costs around €100. It is possible and more cost-effective to split one intramuscular dose of the vaccine into several intradermal doses, but this practice is discouraged by American health authorities.
A major contributor to this article appears to have a close connection with its subject. (February 2015) (Learn how and when to remove this template message)
Aside from vaccinating humans, another approach was also developed by vaccinating dogs to prevent the spread of the virus. In 1979, the Van Houweling Research Laboratory of the Silliman University Medical Center in Dumaguete in the Philippines developed and produced a dog vaccine that gave a three-year immunity from rabies. The development of the vaccine resulted in the elimination of rabies in many parts of the Visayas and Mindanao Islands. The successful program in the Philippines was later used as a model by other countries, such as Ecuador and the Yucatan State of Mexico, in their fight against rabies conducted in collaboration with the World Health Organization.
In Tunisia, a rabies control program was initiated to give dog owners free vaccination to promote mass vaccination which was sponsored by their government. The vaccine is known as Rabisin (Mérial), which is a cell based rabies vaccine only used countrywide. Vaccinations are often administered when owners take in their dogs for check-ups and visits at the vet.
Wildlife species, primarily bats, raccoons, skunks, and foxes, act as reservoir species for different variants of the rabies virus. This results in the general occurrence of rabies as well as outbreaks in animal populations. Approximately 90% of all reported rabies cases in the US are from wildlife.
Oral rabies vaccine
There is an oral vaccination in pellet form which can be left out for wild animals to produce a herd immunity effect. Oral rabies vaccination (ORV) programs have been used in many countries in an effort to control the spread of rabies and limit the risk of human contact with the rabies virus. ORV programs were initiated in Europe in the 1980s, Canada in 1985, and in the United States in 1990. ORV is a preventive measure to eradicate rabies in wild animal vectors of disease, mainly foxes, raccoons, raccoon dogs, coyotes and jackals, but also can be used for dogs in developing countries. ORV programs typically use edible baits to deliver the vaccine to targeted animals. ORV baits consist of a small packet containing the oral vaccine which is then either coated in a fishmeal paste or encased in a fishmeal-polymer block. When an animal bites into the bait, the packets burst and the vaccine is administered. Current research suggests that if adequate amounts of the vaccine is ingested, immunity to the virus should last for upwards of one year. By immunizing wild or stray animals, ORV programs work to create a buffer zone between the rabies virus and potential contact with humans, pets, or livestock. The effectiveness of ORV campaigns in specific areas is determined through trap-and-release methods. Titer tests are performed on the blood drawn from the sample animals in order to measure rabies antibody levels in the blood. Baits are usually distributed by aircraft to more efficiently cover large, rural regions. In order to place baits more precisely and to minimize human and pet contact with baits, however, they are distributed by hand in suburban or urban regions. The potential for human contact with baits is a present concern for OPV programs, but the oral vaccine does not contain the whole rabies virus and has been proven safe in over 60 animal species including cats and dogs. The idea of wildlife vaccination was conceived during the 1960s, and modified-live rabies viruses were used for the experimental oral vaccination of carnivores by the 1970s. The development of safe and effective rabies virus vaccines applied in attractive baits resulted in the first field trials in Switzerland in 1978 to immunize red foxes. ORV programs have seen success in preventing the westward spread of raccoon variant rabies in the United States and even eradicating rabies in red foxes in Switzerland.
Imrab is an example of a veterinary rabies vaccine containing the Pasteur strain of killed rabies virus. Several different types of Imrab exist, including Imrab, Imrab 3, and Imrab Large Animal. Imrab 3 has been approved for ferrets and, in some areas, pet skunks. The reason why these oral vaccines that enter the body through the GI tract are able to convey resistance to rabies is due to the usage of a live human adenovirus type 5 vector. Adenovirus, a common viral pathogen that infects the GI tract and causes diarrhea is genetically altered to express rabies surface proteins, thereby allowing the adenovirus to infect GI tract cells. This enables the viral vector to infect cells in the GI and stimulate a cellular and humoral response that would provide immunity in the case of being bitten by an infected animal and being infected via blood.[medical citation needed]
- "Rabies vaccine, human diploid cell (Imovax Rabies) Use During Pregnancy". Drugs.com. 22 November 2019. Retrieved 29 December 2019.
- "Rabies Vaccine BP - Summary of Product Characteristics (SmPC)". (emc). 28 June 2020. Retrieved 2 November 2020.
- "Rabipur pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). Retrieved 2 November 2020.
- "Imovax Rabies (rabies virus strain pm-1503-3m antigen- propiolactone inactivated and water kit". DailyMed. 21 October 2020. Retrieved 2 November 2020.
- "Rabavert- rabies vaccine kit". DailyMed. 18 September 2019. Retrieved 2 November 2020.
- World Health Organization (2018). "Rabies vaccines: WHO position paper – April 2018". Weekly Epidemiological Record. 93 (16): 201–19. hdl:10665/272372. Lay summary (PDF).
- Nunnally, Brian (2014). Vaccine Analysis: Strategies, Principles, and Control. Springer. p. 63. ISBN 9783662450246. Archived from the original on 5 March 2016.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Preexposure Vaccinations". Centers for Disease Control and Prevention (CDC). 22 April 2011. Retrieved 19 November 2019.
- "Rabies Vaccine Information Statement". Centers for Disease Control and Prevention (CDC). 6 October 2009. Retrieved 27 September 2019.
- "Rabies Postexposure Prophylaxis (PEP)". Centers for Disease Control and Prevention (CDC). 11 June 2019. Retrieved 19 November 2019.
- "An Advisory Committee Statement (ACS). Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on travellers and rabies vaccine" (PDF). Canada Communicable Disease Report (CCDR). 28 (ACS 4): 1–12. March 2002. ISSN 1481-8531. PMID 11889905.
- "National Rabies Management Program Overview". Animal and Plant Health Inspection Service (APHIS). Retrieved 12 November 2019.
- "Rabies - Human Vaccines". World Health Organization (WHO). Archived from the original on 3 November 2012. Retrieved 1 October 2012.
- "Rabies". World Health Organization (WHO). Retrieved 21 November 2019.
- Geison GL (1978). "Pasteur's work on rabies: Reexamining the ethical issues diagnosis for developing countries". Hastings Center Report. The Hastings Center. 8 (April): 26–. doi:10.2307/3560403. JSTOR 3560403. PMID 348641.
- Arnaud Tarantola (2017). "Four Thousand Years of Concepts Relating to Rabies in Animals and Humans, Its Prevention and Its Cure". Trop Med Infect Dis. 2 (2): 5. doi:10.3390/tropicalmed2020005. PMC 6082082. PMID 30270864.
- Plotkin, Stanley A. (1980). "Rabies Vaccine Prepared in Human Cell Cultures: Progress and Perspectives". Reviews of Infectious Diseases. 2 (3): 433–448. doi:10.1093/clinids/2.3.433. PMID 6158081.
- Srivastava, AK; Sardana, V; Prasad, K; Behari, M (March 2004). "Diagnostic dilemma in flaccid paralysis following anti-rabies vaccine". Neurol India. 52 (1): 132–3. PMID 15069272. Archived from the original on 2 August 2009.
- Shlim, David (24 June 2019). "Perspectives: Intradermal Rabies Preexposure Immunization". Centers for Disease Control and Prevention (CDC). Archived from the original on 2 October 2015. Retrieved 26 December 2019.
- "State Rabies Vaccination Laws for Domestic Dogs, Cats, and Ferrets in the United States". lawatlas.org. Retrieved 22 January 2020.
- "Dr. George W. Beran's Biography" Archived 15 April 2010 at the Wayback Machine. World Rabies Day. Retrieved 2010-04-23.
- "One World, One Health Rabies" Archived 2011-07-24 at the Wayback Machine.OneHealthInitiative.com. Retrieved 2010-04-23.
- Touihri; Zaouia, I.; Elhili, K.; Dellagi, K.; Bahloul, C. (23 December 2009). "Evaluation of Mass Vaccination Campaign Coverage Against Rabies in Dogs in Tunisia". Zoonoses and Public Health. Institut Pasteur de Tunis and Blackwell Verlag GmbH. 58 (2): 110–8. doi:10.1111/j.1863-2378.2009.01306.x. PMID 20042063. S2CID 232553.
- "Oral Rabies Vaccination". Animal and Plant Health Inspection Service (APHIS). Retrieved 12 November 2019.
- "What are the signs and symptoms of rabies?". Centers for Disease Control and Prevention (CDC). Archived from the original on 9 November 2015. Retrieved 9 November 2015.
- "Oral Rabies Vaccine Information". Animal and Plant Health Inspection Service (APHIS). 12 November 2019.
- "Oral rabies vaccination". Archived from the original on 7 January 2014. Retrieved 21 February 2014.
- "Frequently Asked Questions". Animal and Plant Health Inspection Service (APHIS). 12 November 2019.
- "Oral Rabies Vaccination Program in the East" (PDF). Animal and Plant Health Inspection Service (APHIS). January 2011.
- Rupprecht CE, Hanlon CA, Slate D (2004). "Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control". Dev Biol (Basel). 119: 173–84. PMID 15742629.
- "Oral Rabies Vaccine Project – Environmental Epidemiology". www.vdh.virginia.gov. Archived from the original on 18 August 2017. Retrieved 23 July 2017.
- "Switzerland's Kind of Gross, Incredibly Effective Anti-Rabies Weapon | Now I Know". nowiknow.com. Archived from the original on 12 February 2016. Retrieved 23 July 2017.
- Merial Archived 9 April 2005 at the Wayback Machine
- Aspen Skunk Rabies Research, Inc. Archived 25 May 2011 at the Wayback Machine
- "Rabies Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC).
- "Imovax". U.S. Food and Drug Administration (FDA). STN: 103931.
- "RabAvert - Rabies Vaccine". U.S. Food and Drug Administration (FDA). STN: BL 103334.
- Rabies Vaccines at the US National Library of Medicine Medical Subject Headings (MeSH)